

Claims:

1. A pharmaceutical composition for use in the treatment of hepatocellular carcinoma, comprising a pharmaceutically effective amount of thalidomide and a pharmaceutical acceptable carrier.

5 2. The pharmaceutical composition according to Claim 1, wherein the pharmaceutically effective amount is 30 to 1200 mg.

3. The pharmaceutical composition according to Claim 2, wherein the pharmaceutically effective amount is 50 to 800 mg.

4. The pharmaceutical composition according to Claim 1 for use in the treatment of metastatic hepatocellular carcinoma of patients who have failed to local treatment.

5. The pharmaceutical composition according to Claim 1, which is used in combination with an additional drug for treating hepatocellular carcinoma, selected from a group consisting of anticancer chemotherapeutic drugs, hormones, biological response modifiers or other angiogenesis inhibitors.

6. The pharmaceutical composition according to Claim 1, which is used in combination with immunotherapy or gene therapy.

7. The pharmaceutical composition according to Claim 1 for use as an adjuvant treating agent in the treatment of hepatocellular carcinoma.

8. The pharmaceutical composition according to Claim 7, wherein the treatment of hepatocellular carcinoma is percutaneous ethanol injection, operation, transcatheter arterial chemoembolization or cryotherapy.